ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OMER vs KRSA // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Omeros Corporation (NASDAQ) VS. Korsana Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: OMER 1 — KRSA 4
■ METRIC PARITY
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OMER VS. KRSA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OMER KRSA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -5.70% -29.30 KRSA /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -8.47% -0.24% -8.23 KRSA /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 3.70% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 2/9 -1.00 KRSA /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.6 45.6 +7.95 OMER /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.37B $1.38B -$4.5M KRSA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OMER REV KRSA REV OMER GROSS % KRSA GROSS % OMER FCF KRSA FCF
FY 2025 $0 $2.1M — — -$116.2M -$3.3M
FY 2024 $0 $2.0M — — -$149.0M -$4.3M
FY 2023 — $0 — — — -$21.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OMER // BETA —
KRSA // BETA —